Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Short-term Investments (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Short-term Investments for 7 consecutive years, with $364.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments rose 45.09% to $364.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $364.0 million, a 45.09% increase, with the full-year FY2024 number at $231.4 million, up 7.26% from a year prior.
  • Short-term Investments was $364.0 million for Q3 2025 at Rhythm Pharmaceuticals, up from $155.4 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $364.0 million in Q3 2025 to a low of $137.9 million in Q2 2023.
  • A 5-year average of $218.5 million and a median of $215.8 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: crashed 31.05% in 2022, then skyrocketed 45.09% in 2025.
  • Rhythm Pharmaceuticals' Short-term Investments stood at $235.6 million in 2021, then dropped by 12.73% to $205.6 million in 2022, then rose by 4.94% to $215.8 million in 2023, then grew by 7.26% to $231.4 million in 2024, then soared by 57.27% to $364.0 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Short-term Investments are $364.0 million (Q3 2025), $155.4 million (Q2 2025), and $208.4 million (Q1 2025).